Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19

Nagasai C. Adusumilli, David Zhang, Joel M. Friedman, Adam J. Friedman

Research output: Contribution to journalReview article

Abstract

The ongoing outbreak of COVID-19 has quickly become a daunting challenge to global health. In the absence of targeted therapy and a reported 5.5% case fatality rate in the United States, treatments preventing rapid cardiopulmonary failure are urgently needed. Clinical features, pathology and homology to better understood pathogens suggest that uncontrolled inflammation and a cytokine storm likely drive COVID-19's unrelenting disease process. Interventions that are protective against acute lung injury and ARDS can play a critical role for patients and health systems during this pandemic. Nitric oxide is an antimicrobial and anti-inflammatory molecule with key roles in pulmonary vascular function in the context of viral infections and other pulmonary disease states. This article reviews the rationale for exogenous nitric oxide use for the pathogenesis of COVID-19 and highlights its potential for contributing to better clinical outcomes and alleviating the rapidly rising strain on healthcare capacity.

Original languageEnglish (US)
Pages (from-to)4-8
Number of pages5
JournalNitric Oxide - Biology and Chemistry
Volume103
DOIs
StatePublished - Oct 1 2020

Keywords

  • ARDS
  • COVID-19
  • Nitric oxide

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Clinical Biochemistry
  • Cancer Research

Fingerprint Dive into the research topics of 'Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19'. Together they form a unique fingerprint.

  • Cite this